Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Incyte (INCY) -- Ignore unavailable to you. Want to Upgrade?

To: RCMac who wrote (932)	3/22/1999 8:56:00 PM
From: A.J. Mullen	Read Replies (2) \| Respond to of 3202

Thankyou very much for the response. From the second paragraph you quote it seems he is specifically ruling out many of the patents that Incyte would have hoped to hold; the "potentially non-enabling." Or I have I misunderstood? On a broader note, My understanding is that patents are issued relatively liberally by the Patent Office, and it's then up to the holder to assert their "rights." If others disagree, then the holder has to take them to court and prove infringement. One defence is that the patent isn't valid. Is that so? What about other countries? At one time European courts were thought likely to be less friendly to the idea of patenting living material. I think they must have come around to the US view or we'd be hearing another potential trade war.